We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

1 hedge funds and large institutions have $2.64M invested in CNS Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

13% less capital invested

Capital invested by funds: $3.04M → $2.64M (-$403K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.8M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.8M
2
Citadel Advisors
Citadel Advisors
Florida
-$221K
3
EIM
Essex Investment Management
Massachusetts
-$142K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$104K
5
Jane Street
Jane Street
New York
-$33K

CNSP Hedge Fund Activity: Q2 2021 in Review

1 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2021, worth a combined $2.64M — down 13% from $3.04M a quarter earlier.

Fund positioning in CNSP was balanced in Q2 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $1.8M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.8M sold.

  • 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $2.64M of CNS Pharmaceuticals stock for Q2 2021, down 13% quarter-over-quarter.
  • 1 fund opened new CNS Pharmaceuticals positions in Q2 2021 and 1 closed out, a net change of 0 holders.
  • The largest CNS Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $1.8M added.
  • The largest CNS Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $1.8M sold.

Based on aggregated 13F filings for Q2 2021.